secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001193125-25-114430
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres Q1 net income $32.7M; SER-155 Phase 2 protocol to FDA in weeks
--------------------------------------------------------------------

- Net income from continuing ops of $32.7M vs net loss of $32.9M YoY, driven by $50M Nestlé installment.
- R&D expense down to $11.8M from $19.5M; G&A down to $11.9M from $14.9M.
- Cash $58.8M at Mar 31, plus $25M Nestlé installment expected July 2025; runway into Q1 2026.
- Plans SER-155 Phase 2 study (248 patients, adaptive design) with interim analysis within 12 months of start.
- Regained Nasdaq compliance after 1-for-20 reverse stock split on April 21, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525114430/0001193125-25-114430-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525114430/d915177d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-114430

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer